<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Cosmet Investig Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Cosmet Investig Dermatol</journal-id><journal-id journal-id-type="publisher-id">ccid</journal-id><journal-title-group><journal-title>Clinical, Cosmetic and Investigational Dermatology</journal-title></journal-title-group><issn pub-type="epub">1178-7015</issn><publisher><publisher-name>Dove</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9440669</article-id><article-id pub-id-type="publisher-id">379577</article-id><article-id pub-id-type="doi">10.2147/CCID.S379577</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Pityriasis Lichenoides Et Varioliformis Acuta and Lymphomatoid Papulosis Type F: A Case Report of Two Entities in One Patient</article-title><alt-title alt-title-type="running-authors">Pomsoong et al</alt-title><alt-title alt-title-type="running-title">Pomsoong et al</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5511-1937</contrib-id><name><surname>Pomsoong</surname><given-names>Cherrin</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9723-0563</contrib-id><name><surname>Suchonwanit</surname><given-names>Poonkiat</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7931-3816</contrib-id><name><surname>Chanprapaph</surname><given-names>Kumutnart</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8336-1834</contrib-id><name><surname>Rattanakaemakorn</surname><given-names>Ploysyne</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8268-8790</contrib-id><name><surname>Rutnin</surname><given-names>Suthinee</given-names></name><xref rid="aff0001" ref-type="aff">1</xref><xref rid="an0001" ref-type="corresp"/></contrib><aff id="aff0001"><label>1</label><institution>Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University</institution>, <addr-line>Bangkok</addr-line>, <country>Thailand</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Suthinee Rutnin, <institution>Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University</institution>, <addr-line>270 Rama VI Road, Ratchathewi</addr-line>, <addr-line>Bangkok</addr-line>, <country>Thailand</country>, <addr-line>10400</addr-line>, <phone>Tel +66-2-2011141</phone>, <fax>Fax +66-2-201-1211</fax>, Email suthinee.rutnin@gmail.com</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>15</volume><fpage>1759</fpage><lpage>1765</lpage><history><date date-type="received"><day>22</day><month>6</month><year>2022</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 Pomsoong et al.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Pomsoong et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><abstract><title>Abstract</title><p>Pityriasis lichenoides et varioliformis acuta (PLEVA) and lymphomatoid papulosis (LyP) are uncommon inflammatory skin disorders that occasionally share clinicopathological features. Differentiating between the two entities remains problematic, and a definitive diagnosis usually requires multi-step investigations, which is an enormous challenge to physicians. We hereby report a rare case of a 22-year-old female patient diagnosed with PLEVA who later developed LyP type F, a new histological variant of LyP. Our report highlights that long-term follow-up is essential to determine associated hematologic malignancies, particularly in cases with recalcitrant or progressive cutaneous lesions of PLEVA and/or LyP.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>chronic inflammatory skin disease</kwd><kwd>CD30 positive lymphoproliferative disorders</kwd><kwd>immunohistochemistry</kwd><kwd>mycosis fungoides</kwd><kwd>pityriasis lichenoides</kwd><kwd>cutaneous lymphoma</kwd></kwd-group><funding-group><award-group><funding-source>
<institution-wrap><institution>financial</institution></institution-wrap>
</funding-source></award-group><funding-statement>The authors received no financial support for this research.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="3"/><ref-count count="22"/><page-count count="7"/></counts></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>Pityriasis lichenoides et varioliformis acuta (PLEVA) and lymphomatoid papulosis (LyP) are uncommon skin disorders categorized as different entities. The former is considered a chronic recurrent inflammatory skin disease&#x000a0;while the latter refers to a primary CD30+ cutaneous lymphoproliferative disorder. Clinically, PLEVA presents with acute to subacute cutaneous eruption of multiple erythematous papules that rapidly progress into polymorphic lesions at various stages of evolution, whereas LyP is characterized by recurrent crops of papulonecrotic lesions. Both disorders predominantly appear on the trunk and extremities and sometimes share similar clinical manifestations, leading to delayed or misdiagnosis.<xref rid="cit0001" ref-type="bibr">1&#x02013;3</xref> Therefore, the correlation between clinical features, histopathology, and immunohistochemistry is essential to distinguish these two conditions. Herein, we report a rare co-occurrence of PLEVA and LyP type F developing in the same patient.</p></sec><sec id="s0002"><title>Case Report</title><p>A 22-year-old female presented with a recurrent pruritic rash on the trunk and all extremities for two months. She had no systemic symptoms and denied family history of the same condition. Dermatological examination revealed multiple discrete erythematous papules with crusted lesions on the trunk and extremities, and some healed with varioliform scars (<xref rid="f0001" ref-type="fig">Figure 1</xref>). Other systems were unremarkable. Skin biopsy taken from a lesion on the left hand demonstrated dense superficial and deep perivascular and interface dermatitis of lymphocytes admixed with some extravasated erythrocytes. Scatter and confluent necrotic keratinocytes, parakeratosis, and exocytosis of lymphocytes into the epidermis were noted (<xref rid="f0002" ref-type="fig">Figure 2</xref>). Lymphocytes were stained positive for CD3, but negative for CD 20, demonstrating that they were T cells. Further immunohistochemistry revealed predominate CD8-positive cytotoxic T cells over CD4-positive T cells and negative for CD 30 staining. (<xref rid="f0003" ref-type="fig">Figure 3</xref>). The clinicopathological findings were consistent with PLEVA. She had been treated with topical corticosteroids, doxycycline 200 mg daily, and narrow-band ultraviolet B (NB-UVB) phototherapy two times/week. After 30 sessions of NB-UVB, the treatment was stopped during the Coronavirus disease pandemic with partially clinical improvement. Methotrexate 10 mg/week had been prescribed for 1 month; however, the treatment was switched to cyclosporine 2.5 mg/kg/day due to leukopenia. After 4 months of treatment, cyclosporine was discontinued because of gastrointestinal discomfort. However, skin lesions gradually improved and were totally cleared within 1 year.<fig position="float" id="f0001" fig-type="figure"><label>Figure 1</label><caption><p>Clinical characteristics of pityriasis lichenoides et varioliformis acuta. Multiple discrete erythematous papules with crusted lesions on the (<bold>A</bold>) trunk and (<bold>B</bold> and <bold>C</bold>) extremities, some healed with varioliform scar.</p></caption><graphic xlink:href="CCID-15-1759-g0001" content-type="print-only" position="float"/></fig><fig position="float" id="f0002" fig-type="figure"><label>Figure 2</label><caption><p>Histopathology of pityriasis lichenoides et varioliformis acuta. (<bold>A</bold>) Dense superficial and deep perivascular infiltrate and interface dermatitis (H&#x00026;E 40X), (<bold>B</bold>) consisting of lymphocytes admixed with extravasated erythrocytes (H&#x00026;E 100X). (<bold>C</bold>) Scatter and confluent necrotic keratinocytes, parakeratosis, and exocytosis of lymphocytes into the epidermis (H&#x00026;E 400X).</p></caption><graphic xlink:href="CCID-15-1759-g0002" content-type="print-only" position="float"/><attrib><bold>Abbreviation</bold>: H&#x00026;E, hematoxylin and eosin.</attrib></fig><fig position="float" id="f0003" fig-type="figure"><label>Figure 3</label><caption><p>Immunohistochemistry of pityriasis lichenoides et varioliformis acuta. Positive (<bold>A</bold>) CD3, (<bold>B</bold>) CD4, and (<bold>C</bold>) CD8 but negative (<bold>D</bold>) CD30 staining of lymphocytes. (x40 original magnification).</p></caption><graphic xlink:href="CCID-15-1759-g0003" content-type="print-only" position="float"/></fig></p><p>Three months following the remission, the patient developed a new waxing and waning rash with no systemic symptoms. Dermatological examination revealed multiple discrete erythematous-to-brownish papules with some central necrotic crusts on the trunk and extremities (<xref rid="f0004" ref-type="fig">Figure 4</xref>). There was no lymphadenopathy and hepatosplenomegaly. Laboratory investigations, including complete blood count, lactate dehydrogenase level, liver and renal function tests were within normal limits. Skin biopsy obtained from the right arm revealed perifollicular infiltrate of large atypical mononuclear cells with abundant cytoplasm and prominent nuclei admixed with lymphocytes, few neutrophils, and eosinophils with folliculotropism (<xref rid="f0005" ref-type="fig">Figure 5</xref>). Immunohistochemistry demonstrated large atypical CD30+ cell infiltrate within the hair follicle and CD3+, CD4+, and CD8+ small lymphocytes in perivascular areas. (<xref rid="f0006" ref-type="fig">Figure 6</xref>). Regarding clinicopathological correlation, the definitive diagnosis was LyP type F. Acitretin 20 mg/day and NB-UVB 2&#x02013;3 times/week were given, and partial remission was observed after nine consecutive months of treatments.<fig position="float" id="f0004" fig-type="figure"><label>Figure 4</label><caption><p>Clinical characteristics of lymphomatoid papulosis. Multiple discrete erythematous-to-brownish papules with some central necrotic crusts on the (<bold>A</bold>) trunk and (<bold>B</bold>) extremities.</p></caption><graphic xlink:href="CCID-15-1759-g0004" content-type="print-only" position="float"/></fig><fig position="float" id="f0005" fig-type="figure"><label>Figure 5</label><caption><p>Histopathology of lymphomatoid papulosis type F. (<bold>A</bold>) Superficial and deep perivascular and perifollicular infiltrate with epidermal hyperplasia and focal hyperkeratosis (H&#x00026;E 100X). (<bold>B</bold>) Perifollicular infiltrate of atypical large mononuclear cells with folliculotropism (H&#x00026;E 400X).</p></caption><graphic xlink:href="CCID-15-1759-g0005" content-type="print-only" position="float"/><attrib><bold>Abbreviation</bold>: H&#x00026;E, hematoxylin and eosin.</attrib></fig><fig position="float" id="f0006" fig-type="figure"><label>Figure 6</label><caption><p>Immunohistochemistry of lymphomatoid papulosis type F. Positive (<bold>A</bold>) CD3, (<bold>B</bold>) CD4, and (<bold>C</bold>) CD8 staining of small lymphocytes in perivascular area. (<bold>D</bold>) Perifollicular and follicular infiltrate of positive CD30 large atypical mononuclear cells (x40 original magnification).</p></caption><graphic xlink:href="CCID-15-1759-g0006" content-type="print-only" position="float"/></fig></p></sec><sec id="s0003"><title>Discussion</title><p>PLEVA, one of pityriasis lichenoides variants, is an uncommon inflammatory skin disease, which may potentially be malignant. It generally presents with an acute-to-subacute eruption of multiple erythematous papules with hemorrhagic necrosis and crusting and often heals with atrophic varioliform scars. The lesions are frequently self-healing; however, recalcitrance may occur.<xref rid="cit0001" ref-type="bibr">1</xref> To confirm the diagnosis, histopathologic examination is required. PLEVA is characterized by interface dermatitis with prominent lymphocytic infiltration and epidermal involvement.<xref rid="cit0004" ref-type="bibr">4</xref> The exact pathogenesis remains unclear; however, immune dysregulation against medications/infectious agents or an evolution to cutaneous T-cell dyscrasia is an accepted hypothesis.<xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0004" ref-type="bibr">4</xref> Despite lacking standard treatment, topical corticosteroids are commonly prescribed as the first-line therapy. Phototherapy, especially NB-UVB, and antibiotics including tetracyclines and erythromycin are also recommended. Low-dose methotrexate and other systemic immunosuppressants are indicated for severe or recalcitrant PLEVA.<xref rid="cit0005" ref-type="bibr">5</xref></p><p>LyP is a rare dermatological condition and classified in primary CD30+ cutaneous lymphoproliferative disorders.<xref rid="cit0006" ref-type="bibr">6</xref> LyP typically presents with recurrent crops of disseminated papulonodular eruptions, which spontaneously regress within weeks to months.<xref rid="cit0007" ref-type="bibr">7</xref>,<xref rid="cit0008" ref-type="bibr">8</xref> Healing lesions appear as transient post-inflammatory hyperpigmented/hypopigmented macules and occasionally form atrophic varioliform scars. LyP is categorized into five subtypes (A to E) according to histologic characteristics, with type A being the classic and most common type (&#x0003e;75%).<xref rid="cit0002" ref-type="bibr">2</xref></p><p>LyP type F or follicular LyP is another rare histologic subtype, although not officially classified in WHO classification. It was firstly introduced by Pierard et al in 1980 and mainly manifests with follicular involvement.<xref rid="cit0009" ref-type="bibr">9</xref> The prevalence of LyP type F is approximately 5.8&#x02013;10% of all LyP cases.<xref rid="cit0010" ref-type="bibr">10</xref> Histologically, it is characterized by perifollicular infiltrate with variable degrees of folliculotropism of CD30+ medium to large atypical lymphocytes. The less common features are follicular epithelial hyperplasia, ruptured hair follicle, follicular mucinosis, and intrafollicular pustules.<xref rid="cit0010" ref-type="bibr">10</xref> The overlapping clinicopathological features between PLEVA, LyP type F, and mycosis fungoides (MF) may exist.<xref rid="cit0011" ref-type="bibr">11</xref>,<xref rid="cit0012" ref-type="bibr">12</xref> Therefore, clinicopathological correlations and further immunohistochemistry are crucial to distinguish among the three conditions (<xref rid="t0001" ref-type="table">Table 1</xref>).<xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0010" ref-type="bibr">10</xref>,<xref rid="cit0013" ref-type="bibr">13&#x02013;15</xref><table-wrap position="float" id="t0001"><label>Table 1</label><caption><p>The Clinicopathological Features and Immunohistochemistry Between Pityriasis Lichenoides Et Varioliformis Acuta, Lymphomatoid Papulosis, and Mycosis Fungoides</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Distinctive Features</th><th align="center" rowspan="1" colspan="1">PLEVA</th><th align="center" rowspan="1" colspan="1">LyP (Type F)</th><th align="center" rowspan="1" colspan="1">Papular MF</th><th align="center" rowspan="1" colspan="1">Folliculotropic MF</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>Clinical manifestations</bold></td><td rowspan="1" colspan="1">- Crusted erythematous papules and vesicles<break/>- Heal with varioliform scar</td><td rowspan="1" colspan="1">- Papulonodular or papulonecrotic lesions</td><td rowspan="1" colspan="1">Monomorphous scaly erythematous papules</td><td rowspan="1" colspan="1">Papules, patches or plaques with follicular accentuation, alopecia, milia</td></tr><tr><td rowspan="1" colspan="1"><bold>Distribution</bold></td><td rowspan="1" colspan="1">Trunk and extremities</td><td rowspan="1" colspan="1">Trunk and extremities</td><td rowspan="1" colspan="1">Trunk and extremities</td><td rowspan="1" colspan="1">Trunk, extremities, head and neck</td></tr><tr><td rowspan="1" colspan="1"><bold>Clinical course</bold></td><td rowspan="1" colspan="1">- Chronic, last indefinitely from weeks to months to years<break/>- Spontaneous resolution</td><td rowspan="1" colspan="1">- Chronic relapsing, last weeks to months<break/>- Spontaneous resolution</td><td rowspan="1" colspan="1">Persistent</td><td rowspan="1" colspan="1">Persistent</td></tr><tr><td rowspan="1" colspan="1"><bold>Histopathological findings</bold></td><td rowspan="1" colspan="1">- Parakeratosis<break/>- Exocytosis of lymphocytes<break/>- Confluent necrotic keratinocytes<break/>- Interface change<break/>- Wedge-shaped superficial and deep infiltrate of CD8+ cytotoxic lymphocytes<break/>- Extravasated erythrocytes</td><td rowspan="1" colspan="1">- Perifollicular infiltrates with variable degree of folliculotropism of medium to large atypical CD30+ cells<break/>- Eosinophils and/or neutrophils</td><td rowspan="1" colspan="1">- Band-like infiltrate of atypical small to medium CD4+ lymphocytes<break/>- Epidermotropism</td><td rowspan="1" colspan="1">- Perifollicular lymphocytic infiltrate<break/>- Folliculotropism of predominately atypical CD4+lymphocytes<break/>- Spare interfollicular epithelium<break/>- Eosinophils and/or plasma cells</td></tr><tr><td colspan="5" rowspan="1"><bold>Immunohistochemistry<sup>a</sup></bold></td></tr><tr><td rowspan="1" colspan="1"><bold>CD4</bold></td><td align="center" rowspan="1" colspan="1">&#x000b1;</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1"><bold>CD8</bold></td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">&#x000b1;</td><td align="center" rowspan="1" colspan="1">&#x000b1;</td><td align="center" rowspan="1" colspan="1">&#x000b1;</td></tr><tr><td rowspan="1" colspan="1"><bold>CD30</bold></td><td align="center" rowspan="1" colspan="1">+ (Rare)</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">+ (Occasional)</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><bold>Notes</bold>: <sup>a</sup>Immunohistochemistry results: + indicates positive staining; &#x02212; indicates negative staining; &#x000b1; indicates positive or negative staining.</p></fn><fn id="tfn0002"><p><bold>Abbreviations</bold>: LyP, lymphomatoid papulosis; MF, mycosis fungoides; PLEVA, pityriasis lichenoides et varioliformis acuta.</p></fn></table-wrap-foot></table-wrap>
</p><p>Since LyP is a recurring condition, and its curative therapy is not available, methotrexate and/or phototherapy, including NB-UVB and psoralen ultraviolet-A are the first-line option for cases with disseminated or recurrent scarring lesions on cosmetically sensitive areas. Methotrexate usually reaches disease control after 3&#x02013;4 weeks, but a relapse rate of up to 40% may occur after its discontinuation.<xref rid="cit0002" ref-type="bibr">2</xref> Recently, a novel targeted therapy, brentuximab (anti-CD30), demonstrated benefit for severe or recalcitrant LyP.<xref rid="cit0016" ref-type="bibr">16</xref> Although various therapeutic managements are established, relapse still occurs. Whether LyP has a 10-year disease-specific survival rate of almost 100%, secondary hematologic malignancies including MF, anaplastic large cell lymphoma, and Hodgkin&#x02019;s lymphoma have been reported in up to 20%. The malignancies may be preceded by, associated with, or followed by LyP.<xref rid="cit0017" ref-type="bibr">17</xref></p><p>We presented a unique case of recalcitrant PLEVA for one year, and developed LyP after 3 months of remission, demonstrating two diseases in one patient. The association between PLEVA and LyP has been proposed but remains debatable.<xref rid="cit0011" ref-type="bibr">11</xref>,<xref rid="cit0018" ref-type="bibr">18</xref> However, clinicopathological and immunohistochemical evidence in the past decade has suggested PLEVA and LyP as distinct disorders.<xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0019" ref-type="bibr">19</xref>,<xref rid="cit0020" ref-type="bibr">20</xref> Currently, there are limited reports of PLEVA and LyP arising in the same patient.<xref rid="cit0021" ref-type="bibr">21</xref>,<xref rid="cit0022" ref-type="bibr">22</xref> Sidiropoulou et al reported the coexistence of LyP type A, PLEVA, and MF over a 15-year period in one case. Different alterations in host immunity leading to discrete clinical expressions were remarked for these three separate entities.<xref rid="cit0021" ref-type="bibr">21</xref> Another case presented with prolonged LyP type B for 11 years followed by PLEVA, reflecting the difference in host immune response to antigenic stimulus.<xref rid="cit0022" ref-type="bibr">22</xref></p><p>In conclusion, we reported a patient with PLEVA followed by LyP type F, a rare co-existence. This case underlined the importance of diagnostic confirmation with the clinicopathological and immunohistochemical distinction between these two entities. It is also essential to recognize histologic characteristics of LyP type F to halt misdiagnosis. Additionally, long-term follow-up and re-biopsy should be considered in progressive or recalcitrant cases in order to give a precise diagnosis, provide proper management, and evaluate for associated secondary hematologic malignancies.</p></sec></body><back><sec id="s0004"><title>Abbreviations</title><p>LyP, lymphomatoid papulosis; MF, mycosis fungoides; NB-UVB, narrow-band ultraviolet B; PLEVA, pityriasis lichenoides et varioliformis acuta.</p></sec><sec id="s0005"><title>Ethics Approval and Informed Consent</title><p>The patient provided written informed consent for the case details and accompanying images to be published. Institutional approval was not required to publish the case details.</p></sec><sec sec-type="COI-statement" id="s0006"><title>Disclosure</title><p>The authors declare no conflicts of interest in this work.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Khachemoune</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Blyumin</surname>
<given-names>ML</given-names></string-name>. <article-title>Pityriasis lichenoides: pathophysiology, classification, and treatment</article-title>. <source><italic toggle="yes">Am J Clin Dermatol</italic></source>. <year>2007</year>;<volume>8</volume>(<issue>1</issue>):<fpage>29</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">17298104</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Martinez-Cabriales</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Walsh</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Sade</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Shear</surname>
<given-names>NH</given-names></string-name>. <article-title>Lymphomatoid papulosis: an update and review</article-title>. <source><italic toggle="yes">J Eur Acad Dermatol Venereol</italic></source>. <year>2020</year>;<volume>34</volume>(<issue>1</issue>):<fpage>59</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">31494989</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Zheng</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Jia</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Tian</surname>
<given-names>Q</given-names></string-name>, et al. <article-title>Lymphomatoid papulosis misdiagnosed as pityriasis lichenoides et varioliformis acuta: two case reports and a literature review</article-title>. <source><italic toggle="yes">Exp Ther Med</italic></source>. <year>2014</year>;<volume>8</volume>(<issue>6</issue>):<fpage>1927</fpage>&#x02013;<lpage>1933</lpage>.<pub-id pub-id-type="pmid">25371758</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Bowers</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Warshaw</surname>
<given-names>EM</given-names></string-name>. <article-title>Pityriasis lichenoides and its subtypes</article-title>. <source><italic toggle="yes">J Am Acad Dermatol</italic></source>. <year>2006</year>;<volume>55</volume>(<issue>4</issue>):<fpage>557</fpage>&#x02013;<lpage>572</lpage>.<pub-id pub-id-type="pmid">17010734</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Bellinato</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Maurelli</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gisondi</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Girolomoni</surname>
<given-names>G</given-names></string-name>. <article-title>A systematic review of treatments for pityriasis lichenoides</article-title>. <source><italic toggle="yes">J Eur Acad Dermatol Venereol</italic></source>. <year>2019</year>;<volume>33</volume>(<issue>11</issue>):<fpage>2039</fpage>&#x02013;<lpage>2049</lpage>.<pub-id pub-id-type="pmid">31318465</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname>
<given-names>HH</given-names></string-name>, <string-name><surname>Lach</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Kadin</surname>
<given-names>ME</given-names></string-name>. <article-title>Epidemiology of lymphomatoid papulosis</article-title>. <source><italic toggle="yes">Cancer</italic></source>. <year>1992</year>;<volume>70</volume>(<issue>12</issue>):<fpage>2951</fpage>&#x02013;<lpage>2957</lpage>.<pub-id pub-id-type="pmid">1451079</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Kempf</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Pfaltz</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Vermeer</surname>
<given-names>MH</given-names></string-name>, et al. <article-title>EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma</article-title>. <source><italic toggle="yes">Blood</italic></source>. <year>2011</year>;<volume>118</volume>(<issue>15</issue>):<fpage>4024</fpage>&#x02013;<lpage>4035</lpage>.<pub-id pub-id-type="pmid">21841159</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Kempf</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Kerl</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Mitteldorf</surname>
<given-names>C</given-names></string-name>. <article-title>Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment</article-title>. <source><italic toggle="yes">Semin Cutan Med Surg</italic></source>. <year>2018</year>;<volume>37</volume>(<issue>1</issue>):<fpage>24</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">29719017</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Pierard</surname>
<given-names>GE</given-names></string-name>, <string-name><surname>Ackerman</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Lapiere</surname>
<given-names>CM</given-names></string-name>. <article-title>Follicular lymphomatoid papulosis</article-title>. <source><italic toggle="yes">Am J Dermatopathol</italic></source>. <year>1980</year>;<volume>2</volume>(<issue>2</issue>):<fpage>173</fpage>&#x02013;<lpage>180</lpage>.<pub-id pub-id-type="pmid">7246982</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Kempf</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Kazakov</surname>
<given-names>DV</given-names></string-name>, <string-name><surname>Baumgartner</surname>
<given-names>HP</given-names></string-name>, <string-name><surname>Kutzner</surname>
<given-names>H</given-names></string-name>. <article-title>Follicular lymphomatoid papulosis revisited: a study of 11 cases, with new histopathological findings</article-title>. <source><italic toggle="yes">J Am Acad Dermatol</italic></source>. <year>2013</year>;<volume>68</volume>(<issue>5</issue>):<fpage>809</fpage>&#x02013;<lpage>816</lpage>.<pub-id pub-id-type="pmid">23375516</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Vonderheid</surname>
<given-names>EC</given-names></string-name>, <string-name><surname>Kadin</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Telang</surname>
<given-names>GH</given-names></string-name>. <article-title>Commentary about papular mycosis fungoides, lymphomatoid papulosis and lymphomatoid pityriasis lichenoides: more similarities than differences</article-title>. <source><italic toggle="yes">J Cutan Pathol</italic></source>. <year>2016</year>;<volume>43</volume>(<issue>4</issue>):<fpage>303</fpage>&#x02013;<lpage>312</lpage>.<pub-id pub-id-type="pmid">26566599</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Borra</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Custrin</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Saggini</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Pityriasis Lichenoides, Atypical Pityriasis Lichenoides, and Related Conditions: a Study of 66 Cases</article-title>. <source><italic toggle="yes">Am J Surg Pathol</italic></source>. <year>2018</year>;<volume>42</volume>(<issue>8</issue>):<fpage>1101</fpage>&#x02013;<lpage>1112</lpage>.<pub-id pub-id-type="pmid">29851705</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Kodama</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Fink-Puches</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Massone</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Kerl</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Cerroni</surname>
<given-names>L</given-names></string-name>. <article-title>Papular mycosis fungoides: a new clinical variant of early mycosis fungoides</article-title>. <source><italic toggle="yes">J Am Acad Dermatol</italic></source>. <year>2005</year>;<volume>52</volume>(<issue>4</issue>):<fpage>694</fpage>&#x02013;<lpage>698</lpage>.<pub-id pub-id-type="pmid">15793526</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Mitteldorf</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Stadler</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Sander</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Kempf</surname>
<given-names>W</given-names></string-name>. <article-title>Folliculotropic mycosis fungoides</article-title>. <source><italic toggle="yes">J Dtsch Dermatol Ges</italic></source>. <year>2018</year>;<volume>16</volume>(<issue>5</issue>):<fpage>543</fpage>&#x02013;<lpage>557</lpage>.<pub-id pub-id-type="pmid">29726638</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Ross</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Truong</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Keller</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Mulholland</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>JB</given-names></string-name>, <string-name><surname>Sahu</surname>
<given-names>J</given-names></string-name>. <article-title>Follicular Lymphomatoid Papulosis: an Eosinophilic-Rich Follicular Subtype Masquerading as Folliculitis Clinically and Histologically</article-title>. <source><italic toggle="yes">Am J Dermatopathol</italic></source>. <year>2016</year>;<volume>38</volume>(<issue>1</issue>):<fpage>e1</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">26730698</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Lewis</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Talpur</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Huen</surname>
<given-names>AO</given-names></string-name>, <string-name><surname>Tetzlaff</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Duvic</surname>
<given-names>M</given-names></string-name>. <article-title>Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: an Analysis of Phase 2 Results</article-title>. <source><italic toggle="yes">JAMA Dermatol</italic></source>. <year>2017</year>;<volume>153</volume>(<issue>12</issue>):<fpage>1302</fpage>&#x02013;<lpage>1306</lpage>.<pub-id pub-id-type="pmid">28980004</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Wieser</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Oh</surname>
<given-names>CW</given-names></string-name>, <string-name><surname>Talpur</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Duvic</surname>
<given-names>M</given-names></string-name>. <article-title>Lymphomatoid papulosis: treatment response and associated lymphomas in a study of 180 patients</article-title>. <source><italic toggle="yes">J Am Acad Dermatol</italic></source>. <year>2016</year>;<volume>74</volume>(<issue>1</issue>):<fpage>59</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">26518172</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Black</surname>
<given-names>MM</given-names></string-name>. <article-title>Lymphomatoid papulosis and pityriasis lichenoides: are they related?</article-title>
<source><italic toggle="yes">Br J Dermatol</italic></source>. <year>1982</year>;<volume>106</volume>(<issue>6</issue>):<fpage>717</fpage>&#x02013;<lpage>721</lpage>.<pub-id pub-id-type="pmid">7082579</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Willemze</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Scheffer</surname>
<given-names>E</given-names></string-name>. <article-title>Clinical and histologic differentiation between lymphomatoid papulosis and pityriasis lichenoides</article-title>. <source><italic toggle="yes">J Am Acad Dermatol</italic></source>. <year>1985</year>;<volume>13</volume>(<issue>3</issue>):<fpage>418</fpage>&#x02013;<lpage>428</lpage>.<pub-id pub-id-type="pmid">4056116</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Jang</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>Choi</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Choi</surname>
<given-names>JH</given-names></string-name>. <article-title>Expression of cutaneous lymphocyte-associated antigen and TIA-1 by lymphocytes in pityriasis lichenoides et varioliformis acuta and lymphomatoid papulosis: immunohistochemical study</article-title>. <source><italic toggle="yes">J Cutan Pathol</italic></source>. <year>2001</year>;<volume>28</volume>(<issue>9</issue>):<fpage>453</fpage>&#x02013;<lpage>459</lpage>.<pub-id pub-id-type="pmid">11553311</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Sidiropoulou</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Nikolaou</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Marinos</surname>
<given-names>L</given-names></string-name>, et al. <article-title>A case of lymphomatoid papulosis, pityriasis lichenoides acuta, and mycosis fungoides coexistence</article-title>. <source><italic toggle="yes">Australas J Dermatol</italic></source>. <year>2019</year>;<volume>60</volume>(<issue>2</issue>):<fpage>e154</fpage>&#x02013;<lpage>e156</lpage>.<pub-id pub-id-type="pmid">30198062</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Vonderheid</surname>
<given-names>EC</given-names></string-name>, <string-name><surname>Kadin</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Gocke</surname>
<given-names>CD</given-names></string-name>. <article-title>Lymphomatoid papulosis followed by pityriasis lichenoides: a common pathogenesis?</article-title>
<source><italic toggle="yes">Am J Dermatopathol</italic></source>. <year>2011</year>;<volume>33</volume>(<issue>8</issue>):<fpage>835</fpage>&#x02013;<lpage>840</lpage>.<pub-id pub-id-type="pmid">22042257</pub-id></mixed-citation></ref></ref-list></back></article>
